UK Authortity To Spend £18.7 Million To Make Gilead Sciences, Inc. (GILD)'s Sovaldi Available To Most Grave Patients
4/18/2014 7:05:54 AM
NHS England is to spend £18.7 million to make new Hepatitis C treatment Sovaldi available to patients with the most advanced disease. Around 500 patients who have acute liver failure, and/or awaiting liver transplantation, are set to benefit from the decision to fund Gilead’s Sovaldi (sofosbuvir). The hepatitis C virus causes inflammation of the liver, affecting its ability to function. Whilst many sufferers naturally clear their infections within six months, others develop chronic hepatitis which is usually life-long without therapy.
Help employers find you! Check out all the jobs and post your resume.
comments powered by